Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996

Am J Hematol. 2021 Sep 1;96(9):E334-E338. doi: 10.1002/ajh.26253. Epub 2021 Jun 9.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • DNA-Binding Proteins / genetics*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Histone-Lysine N-Methyltransferase / genetics*
  • Humans
  • Male
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Prognosis
  • Survival Analysis
  • Transcriptional Elongation Factors / genetics*

Substances

  • BCR-ABL1 fusion protein, human
  • DNA-Binding Proteins
  • KMT2A protein, human
  • Oncogene Proteins, Fusion
  • Transcriptional Elongation Factors
  • Myeloid-Lymphoid Leukemia Protein
  • AFF1 protein, human
  • Histone-Lysine N-Methyltransferase
  • Fusion Proteins, bcr-abl

Associated data

  • ClinicalTrials.gov/NCT00439920
  • ClinicalTrials.gov/NCT00537550
  • ClinicalTrials.gov/NCT00458848
  • ClinicalTrials.gov/NCT00475280
  • ClinicalTrials.gov/NCT01156883
  • ClinicalTrials.gov/NCT02067143